Keywords:
ХОБЛ, ИЛ-8, ИЛ-18, MMP-9, sRAGE, биомаркеры.References
1. Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019;381:1248–1256.
2. Agustí A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med. 2011;183:1129–1137.
3. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586.
4. Dima E, Koltsida O, Katsaounou P, et al. Implication of interleukin (IL)-18 in the pathogenesis of chronic obstructive pulmonary disease (COPD). Cytokine. 2015;74:313–317.
5. Dimic-Janjic S, Hoda MA, Milenkovic B, et al. The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. Eur J Med Res. 2023;28:127.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2025 Report. 2025.
7. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70–e88.
8. Hao W, Li M, Pang Y, Du W, Huang X. Increased chemokines levels in patients with chronic obstructive pulmonary disease: correlation with quantitative computed tomography metrics. Br J Radiol. 2021;94:20201030.
9. Imaoka H, Hoshino T, Takei S, et al. Interleukin-18 production and pulmonary function in COPD. Eur Respir J. 2008;31:287–297.
10. Ji W, Akel Bilgic H, van den Berge M, et al. Epithelial cells in chronic obstructive pulmonary disease exacerbations: targets for lung repair. Pharmacol Rev. 2026;78:100131.
11. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–654.
12. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumour necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530–534.
13. Regan EA, Hersh CP, Castaldi PJ, et al. Omics and the search for blood biomarkers in chronic obstructive pulmonary disease. Insights from COPD-Gene. Am J Respir Cell Mol Biol. 2019;61:143–149.
14. Sin S, Lim M-N, Kim J, Bak SH, Kim WJ. Association between plasma sRAGE and emphysema according to the genotypes of the AGER gene. BMC Pulm Med. 2022;22:58.
15. Vanfleteren LEGW, Weidner J, Franssen FME, et al. Biomarker-based clustering of patients with chronic obstructive pulmonary disease. ERJ Open Res. 2023;9:00301–2022.
16. Wells JM, Parker MM, Oster RA, et al. Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI Insight. 2018;3:e123614.
17. Yonchuk JG, Silverman EK, Bowler RP, et al. Circulating soluble receptor for advanced glycation end products as a biomarker of emphysema and the RAGE axis in the lung. Am J Respir Crit Care Med. 2015;192:785–792.
